Reply

Alzheimer’s disease: Molecular consequences of presenilin-1 mutation

C. Russo, G. Schettini, T. C. Saido, C. Hulette, C. Lippa, L. Lannfelt, Bernardino Ghetti, P. Gambetti, M. Tabaton, J. K. Teller

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Gandy et al. compare our results with their 1994 findings that the amino-terminally truncated amyloid Aβ11-42 was relatively abundant in two cases of familial Alzheimer′s disease involving two distinct mutations in -APP. However, four important differences should be borne in mind: The authors compare Aβ11-42 with Aβ1-42 and ignore Aβ1-40, although both Aβ1-40 and Aβ1-42 are generated by β-secretase/BACE cleavage at residue Asp 1 (ref. 3); their data are not correlated with features related to disease severity, such as age at onset and duration; they did not examine brains with PS1 mutations (these were not known at that time); and their characterization was based on the use of size-exclusion chromatography and electrospray mass spectrometry to quantify formic-acid-extracted Aβ, whereas we used quantitative analysis of immunoprecipitated water-soluble Aβ on western blots, mass spectrometry to identify Aβ variants, and immunohistochemistry to reveal amino-truncated A peptides in plaques.

Original languageEnglish (US)
Pages (from-to)655
Number of pages1
JournalNature
Volume411
Issue number6838
DOIs
StatePublished - Jun 7 2001
Externally publishedYes

Fingerprint

Presenilin-1
formic acid
Mass Spectrometry
Alzheimer Disease
Amyloid Precursor Protein Secretases
Mutation
Age of Onset
Amyloid
Gel Chromatography
Western Blotting
Immunohistochemistry
Peptides
Water
Brain

ASJC Scopus subject areas

  • Medicine(all)
  • General

Cite this

Russo, C., Schettini, G., Saido, T. C., Hulette, C., Lippa, C., Lannfelt, L., ... Teller, J. K. (2001). Reply: Alzheimer’s disease: Molecular consequences of presenilin-1 mutation. Nature, 411(6838), 655. https://doi.org/10.1038/35079684

Reply : Alzheimer’s disease: Molecular consequences of presenilin-1 mutation. / Russo, C.; Schettini, G.; Saido, T. C.; Hulette, C.; Lippa, C.; Lannfelt, L.; Ghetti, Bernardino; Gambetti, P.; Tabaton, M.; Teller, J. K.

In: Nature, Vol. 411, No. 6838, 07.06.2001, p. 655.

Research output: Contribution to journalComment/debate

Russo, C, Schettini, G, Saido, TC, Hulette, C, Lippa, C, Lannfelt, L, Ghetti, B, Gambetti, P, Tabaton, M & Teller, JK 2001, 'Reply: Alzheimer’s disease: Molecular consequences of presenilin-1 mutation', Nature, vol. 411, no. 6838, pp. 655. https://doi.org/10.1038/35079684
Russo C, Schettini G, Saido TC, Hulette C, Lippa C, Lannfelt L et al. Reply: Alzheimer’s disease: Molecular consequences of presenilin-1 mutation. Nature. 2001 Jun 7;411(6838):655. https://doi.org/10.1038/35079684
Russo, C. ; Schettini, G. ; Saido, T. C. ; Hulette, C. ; Lippa, C. ; Lannfelt, L. ; Ghetti, Bernardino ; Gambetti, P. ; Tabaton, M. ; Teller, J. K. / Reply : Alzheimer’s disease: Molecular consequences of presenilin-1 mutation. In: Nature. 2001 ; Vol. 411, No. 6838. pp. 655.
@article{16b8a85f73b14c84a5d7925b8a840e3b,
title = "Reply: Alzheimer’s disease: Molecular consequences of presenilin-1 mutation",
abstract = "Gandy et al. compare our results with their 1994 findings that the amino-terminally truncated amyloid Aβ11-42 was relatively abundant in two cases of familial Alzheimer′s disease involving two distinct mutations in -APP. However, four important differences should be borne in mind: The authors compare Aβ11-42 with Aβ1-42 and ignore Aβ1-40, although both Aβ1-40 and Aβ1-42 are generated by β-secretase/BACE cleavage at residue Asp 1 (ref. 3); their data are not correlated with features related to disease severity, such as age at onset and duration; they did not examine brains with PS1 mutations (these were not known at that time); and their characterization was based on the use of size-exclusion chromatography and electrospray mass spectrometry to quantify formic-acid-extracted Aβ, whereas we used quantitative analysis of immunoprecipitated water-soluble Aβ on western blots, mass spectrometry to identify Aβ variants, and immunohistochemistry to reveal amino-truncated A peptides in plaques.",
author = "C. Russo and G. Schettini and Saido, {T. C.} and C. Hulette and C. Lippa and L. Lannfelt and Bernardino Ghetti and P. Gambetti and M. Tabaton and Teller, {J. K.}",
year = "2001",
month = "6",
day = "7",
doi = "10.1038/35079684",
language = "English (US)",
volume = "411",
pages = "655",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6838",

}

TY - JOUR

T1 - Reply

T2 - Alzheimer’s disease: Molecular consequences of presenilin-1 mutation

AU - Russo, C.

AU - Schettini, G.

AU - Saido, T. C.

AU - Hulette, C.

AU - Lippa, C.

AU - Lannfelt, L.

AU - Ghetti, Bernardino

AU - Gambetti, P.

AU - Tabaton, M.

AU - Teller, J. K.

PY - 2001/6/7

Y1 - 2001/6/7

N2 - Gandy et al. compare our results with their 1994 findings that the amino-terminally truncated amyloid Aβ11-42 was relatively abundant in two cases of familial Alzheimer′s disease involving two distinct mutations in -APP. However, four important differences should be borne in mind: The authors compare Aβ11-42 with Aβ1-42 and ignore Aβ1-40, although both Aβ1-40 and Aβ1-42 are generated by β-secretase/BACE cleavage at residue Asp 1 (ref. 3); their data are not correlated with features related to disease severity, such as age at onset and duration; they did not examine brains with PS1 mutations (these were not known at that time); and their characterization was based on the use of size-exclusion chromatography and electrospray mass spectrometry to quantify formic-acid-extracted Aβ, whereas we used quantitative analysis of immunoprecipitated water-soluble Aβ on western blots, mass spectrometry to identify Aβ variants, and immunohistochemistry to reveal amino-truncated A peptides in plaques.

AB - Gandy et al. compare our results with their 1994 findings that the amino-terminally truncated amyloid Aβ11-42 was relatively abundant in two cases of familial Alzheimer′s disease involving two distinct mutations in -APP. However, four important differences should be borne in mind: The authors compare Aβ11-42 with Aβ1-42 and ignore Aβ1-40, although both Aβ1-40 and Aβ1-42 are generated by β-secretase/BACE cleavage at residue Asp 1 (ref. 3); their data are not correlated with features related to disease severity, such as age at onset and duration; they did not examine brains with PS1 mutations (these were not known at that time); and their characterization was based on the use of size-exclusion chromatography and electrospray mass spectrometry to quantify formic-acid-extracted Aβ, whereas we used quantitative analysis of immunoprecipitated water-soluble Aβ on western blots, mass spectrometry to identify Aβ variants, and immunohistochemistry to reveal amino-truncated A peptides in plaques.

UR - http://www.scopus.com/inward/record.url?scp=84984752292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984752292&partnerID=8YFLogxK

U2 - 10.1038/35079684

DO - 10.1038/35079684

M3 - Comment/debate

VL - 411

SP - 655

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6838

ER -